181 related articles for article (PubMed ID: 2143474)
1. An investigation of factors that might influence the radiochemical purity and stability of 99mTc-MAG3.
Millar AM; O'Brien LM
Eur J Nucl Med; 1990; 16(8-10):615-9. PubMed ID: 2143474
[TBL] [Abstract][Full Text] [Related]
2. Preparation of the renal function and imaging agent 99mTc-MAG3 starting from S-unprotected mercaptoacetyltriglycine.
Noll B; Johannsen B; May K; Spies H
Int J Rad Appl Instrum A; 1992 Jul; 43(7):899-901. PubMed ID: 1321100
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the hepatobiliary excretion of technetium-99m-MAG3 and reconstitution factors affecting radiochemical purity.
Shattuck LA; Eshima D; Taylor AT; Anderson TL; Graham DL; Latino FA; Payne SE
J Nucl Med; 1994 Feb; 35(2):349-55. PubMed ID: 8295009
[TBL] [Abstract][Full Text] [Related]
4. Kit preparation of technetium-99m-mercaptoacetyltriglycine: analysis, biodistribution and comparison with technetium-99m-DTPA in patients with impaired renal function.
Bannister KM; Penglis S; Bellen JC; Baker RJ; Chatterton BE
J Nucl Med; 1990 Sep; 31(9):1568-73. PubMed ID: 2144317
[TBL] [Abstract][Full Text] [Related]
5. Technetium-99m labeled renal function and imaging agents: III. Synthesis of 99mTc-MAG3 and biodistribution of by-products.
Brandau W; Bubeck B; Eisenhut M; Taylor DM
Int J Rad Appl Instrum A; 1988; 39(2):121-9. PubMed ID: 2833469
[TBL] [Abstract][Full Text] [Related]
6. Comparison of technetium-99m MAG3 kit with HPLC-purified technetium-99m MAG3 and OIH in rats.
Coveney JR; Robbins MS
J Nucl Med; 1987 Dec; 28(12):1881-7. PubMed ID: 2960790
[TBL] [Abstract][Full Text] [Related]
7. 99Tcm-MAG3: in vitro stability and in vivo behaviour at different times after preparation.
Millar AM; Wilkinson AG; McAteer E; Best JJ
Nucl Med Commun; 1990 Jun; 11(6):405-12. PubMed ID: 2143569
[TBL] [Abstract][Full Text] [Related]
8. Effects of generator eluate age on the radiochemical purity of fractionated 99Tcm-MAG3.
Hung JC; Thorson LM
Nucl Med Commun; 1995 Mar; 16(3):157-60. PubMed ID: 7770239
[TBL] [Abstract][Full Text] [Related]
9. Technetium-99m (99mTc) mercaptoacetyltriglycine: update on the new 99mTc renal tubular function agent.
Eshima D; Taylor A
Semin Nucl Med; 1992 Apr; 22(2):61-73. PubMed ID: 1534184
[TBL] [Abstract][Full Text] [Related]
10. Effect of source and age of sodium pertechnetate Tc 99m on radiochemical purity of technetium Tc 99m exametazime.
Millar AM
Am J Hosp Pharm; 1993 Jan; 50(1):103-6. PubMed ID: 8381258
[TBL] [Abstract][Full Text] [Related]
11. A simple two-strip method to determine the radiochemical purity of technetium-99m mercaptoacetyltriglycine.
Chen F; Decristoforo C; Rohrbacher B; Riccabona G
Eur J Nucl Med; 1993 Apr; 20(4):334-8. PubMed ID: 8491226
[TBL] [Abstract][Full Text] [Related]
12. Preparation of 99mTc-MAG3: radiochemical purity is affected by the residence time of sodium chloride injection in a three-part syringe.
Waight CC; Beattie LA; O'Brien LM; Millar AM
Nucl Med Commun; 2006 Feb; 27(2):197-200. PubMed ID: 16404235
[TBL] [Abstract][Full Text] [Related]
13. Preparation of 99Tcm-MAG3: no confirmation that sodium chloride injections from plastic containers affect radiochemical purity.
Millar AM; O'Brien LM
Nucl Med Commun; 1998 May; 19(5):475-7. PubMed ID: 9853337
[TBL] [Abstract][Full Text] [Related]
14. Technetium-99m MAG3 kit formulation: preliminary results in normal volunteers and patients with renal failure.
Taylor A; Eshima D; Christian PE; Wooten WW; Hansen L; McElvany K
J Nucl Med; 1988 May; 29(5):616-22. PubMed ID: 2967353
[TBL] [Abstract][Full Text] [Related]
15. The difference in clearance between kit-prepared technetium-99m-MAG3 and radioiodinated hippuric acid.
Bubeck B; Brandau W
J Nucl Med; 1991 Aug; 32(8):1642-4. PubMed ID: 1831230
[No Abstract] [Full Text] [Related]
16. Transplant renography: 99m-Tc-DTPA versus 99m-Tc-MAG3. A preliminary note.
Fraile M; Castell J; Buxeda M; Cuartero A; Cantarell C; Domenech-Torné FM
Eur J Nucl Med; 1989; 15(12):776-9. PubMed ID: 2533892
[TBL] [Abstract][Full Text] [Related]
17. The utility of 99mTc-mercaptoacetyltriglycine in captopril renography.
Taylor A; Martin LG
Am J Hypertens; 1991 Dec; 4(12 Pt 2):731S-736S. PubMed ID: 1837994
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of residual fractions of L,L-ethylcysteinate dimer (Neurolite) for the preparation of 99Tc(m)-L,L-ethylcysteinate dimer.
Verbeke K; Boonen C; Verbruggen A
Nucl Med Commun; 1997 Jun; 18(6):535-9. PubMed ID: 9259524
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the renal excretion characteristics of technetium-99m mercaptoacetylglycyl-D-alanylglycine in healthy volunteers.
Bormans GM; Cleynhen BJ; De Roo MJ; Verbruggen AM
Eur J Nucl Med; 1992; 19(4):271-7. PubMed ID: 1534544
[TBL] [Abstract][Full Text] [Related]
20. The effect on radiochemical purity of modifications to the method of preparation and dilution of 99mTc-sestamibi.
Cooper M; Dustan K; Rotureau L
Nucl Med Commun; 2006 May; 27(5):455-60. PubMed ID: 16609357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
